


**What is claimed:**

1. A compound of Formula I:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $C_{1-8}$  alkyl;

$R^4$  is halogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

$R^6$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is  $-(CH_2)_{1-8}-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,

$-C(=S)NH-$ ,  $-S(=O)_2-CH_3$ ,  $C(=O)-NH-$ ,  $-S(=O)_2-NR^9R^{10}$ ,  $-C(=O)C_{1-8}$  alkyl or

$-C(=O)CH(NH_2)CH_3$ ;

$R^9$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;

$R^{10}$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;

$R^5$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl,  $C_{1-8}$  alkenyl, substituted  $C_{1-8}$  alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;


$R^7$  is  $-OH$  or halogen; and

$R^8$  is hydrogen, halogen or  $C_{1-8}$  alkyl,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen,  $Z$  is not present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen

for use in preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

2. Use of a compound of Formula I:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen,  $-OH$  or halogen;

$R^3$  is hydrogen,  $-OH$ , halogen or  $C_{1-8}$  alkyl;

$R^4$  is halogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

$R^6$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is  $-(CH_2)_{1-8}-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,

$-C(=S)NH-$ ,  $-S(=O)_2-CH_3$ ,  $C(=O)-NH-$ ,  $-S(=O)_2-NR^9R^{10}$ ,  $-C(=O)C_{1-8}$  alkyl or

$-C(=O)CH(NH_2)CH_3$ ;

$R^9$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;

$R^{10}$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;

$R^5$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl,  $C_{1-8}$  alkenyl, substituted  $C_{1-8}$  alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;


$R^7$  is  $-OH$  or halogen; and

$R^8$  is hydrogen, halogen or  $C_{1-8}$  alkyl,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen, Z is not present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen

in the manufacture of a medicament for preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

3. A compound of Formula II:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen,  $-OH$  or halogen;

$R^3$  is hydrogen,  $-OH$ , halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

$R^6$  is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is  $-(CH_2)-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,

$-S(=O)_2-CH_3$ ,  $C(=O)-NH-$ ,  $-S(=O)_2NR^9R^{10}$ ,  $-C(=S)-NH-$  or  $-C(=O)_2-CH_3$ ,

$R^9$  is hydrogen or  $CH_3$ ;

$R^{10}$  is hydrogen or  $CH_3$ ;

$R^5$  is hydrogen or aminophenylalkyl;


$R^7$  is  $-OH$  or halogen; and

$R^8$  is hydrogen, halogen or  $-CH_3$ ,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is halogen, Z is not present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen

for use in preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

4. Use of a compound of Formula II:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

$R^6$  is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is  $-(CH_2)-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,

$-S(=O)_2-CH_3$ ,  $C(=O)-NH-$ ,  $-S(=O)_2NR^9R^{10}$ ,  $-C(=S)-NH-$  or  $-C(=O)_2-CH_3$ ,

$R^9$  is hydrogen or  $CH_3$ ;

$R^{10}$  is hydrogen or  $CH_3$ ;

$R^5$  is hydrogen or aminophenylalkyl;


$R^7$  is -OH or halogen; and

$R^8$  is hydrogen, halogen or  $-CH_3$ ,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is halogen, Z is not present,  $R^7$  is -OH,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen

in the manufacture of a medicament for preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

5. A compound of Formula III:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

$R^7$  is -OH or halogen; and


$R^8$  is hydrogen, halogen or  $-CH_3$ ,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen,

$R^7$  is -OH and  $R^6$  and  $R^8$  are hydrogen

for use in preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

6. Use of a compound of Formula III:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

$R^7$  is -OH or halogen; and


$R^8$  is hydrogen, halogen or  $-CH_3$ ,











provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen,


$R^7$  is -OH and  $R^6$  and  $R^8$  are hydrogen








in the manufacture of a medicament for preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.


7. A compound of:






















































or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof for use in preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.







8. Use of a compound of:

























27



















HCl




HCl






or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof in the manufacture of a medicament for preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same.

9. The compound of Claim 7, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

10. The use of Claim 8, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

11. The compound of Claim 7, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

12. The use of Claim 8, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

13. The compound of Claim 7, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

14. The use of Claim 8, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

15. The compound of Claim 7, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

16. The use of Claim 8, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

17. The compound of Claim 7, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.

18. The use of Claim 8, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.


19. The compound of Claim 1, wherein the lysosomal storage disease is Niemann-Pick disease.

20. The use of Claim 2, wherein the lysosomal storage disease is Niemann-Pick disease.

21. The compound of Claim 1, wherein the lysosomal storage disease is Gaucher's disease.


22. The use of Claim 2, wherein the lysosomal storage disease is Gaucher's disease.

23. A compound



or a pharmaceutically acceptable salt, or solvate thereof for use in preventing and/or treating Gaucher's disease in a patient at risk for developing or diagnosed with the same.


24. Use of a compound



or a pharmaceutically acceptable salt, or solvate thereof in the manufacture of a medicament for preventing and/or treating Gaucher's disease in a patient at risk for developing or diagnosed with the same.

25. A kit comprising:

- a container having an effective amount of a compound of Formula I:



wherein:

R<sup>1</sup> is C(R<sup>2</sup>)(R<sup>3</sup>)(R<sup>4</sup>);

R<sup>2</sup> is hydrogen, -OH or halogen;

R<sup>3</sup> is hydrogen, -OH, halogen or C<sub>1-8</sub> alkyl;

R<sup>4</sup> is halogen, C<sub>1-8</sub> alkyl, substituted C<sub>1-8</sub> alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

R<sup>3</sup> and R<sup>4</sup> may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

R<sup>6</sup> is hydrogen, C<sub>1-8</sub> alkyl, substituted C<sub>1-8</sub> alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is -(CH<sub>2</sub>)<sub>1-8</sub>-, -C(=O)-, -S(=O)<sub>2</sub>NH-, -S(=O)<sub>2</sub>-,

-C(=S)NH-, -S(=O)<sub>2</sub>-CH<sub>3</sub>, C(=O)-NH-, -S(=O)<sub>2</sub>-NR<sup>9</sup>R<sup>10</sup>, -C(=O)C<sub>1-8</sub> alkyl or

-C(=O)CH(NH<sub>2</sub>)CH<sub>3</sub>;

R<sup>9</sup> is hydrogen, C<sub>1-8</sub> alkyl or substituted C<sub>1-8</sub> alkyl;

R<sup>10</sup> is hydrogen, C<sub>1-8</sub> alkyl or substituted C<sub>1-8</sub> alkyl;

R<sup>5</sup> is hydrogen, C<sub>1-8</sub> alkyl, substituted C<sub>1-8</sub> alkyl, aryl, substituted aryl, C<sub>1-8</sub> alkenyl, substituted C<sub>1-8</sub> alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;

R<sup>7</sup> is -OH or halogen; and


R<sup>8</sup> is hydrogen, halogen or C<sub>1-8</sub> alkyl,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen, Z is not present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof;

- instructions for using the same to prevent and/or treat a lysosomal storage disorder.

26. The kit of Claim 25, wherein the lysosomal storage disorder is Gaucher's disease.

27. The kit of Claim 26, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

## CLAIMS

### What is claimed is:

1. Use of a compound of Formula I:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $C_{1-8}$  alkyl;

$R^4$  is halogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl, alkylcycloalkyl or substituted alkylcycloalkyl;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted, preferably with halogen and more preferably with one or more fluorine atoms;

$R^6$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, arylalkyl, substituted arylalkyl, alkylaryl, or substituted alkylaryl;

Z is optional, when present Z is  $-(CH_2)_{1-8}-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,  $-C(=S)NH-$ ,  $-S(=O)_2CH_2-$ ,  $C(=O)-NH-$ ,  $-S(=O)_2NR^9-$ ,  $-C(=O)C_{1-8}$  alkylene or  $-C(=O)CH(NH_2)CH_2-$ ;

$R^9$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;


$R^{10}$  is hydrogen,  $C_{1-8}$  alkyl or substituted  $C_{1-8}$  alkyl;

$R^5$  is hydrogen,  $C_{1-8}$  alkyl, substituted  $C_{1-8}$  alkyl, aryl, substituted aryl,  $C_{1-8}$  alkenyl, substituted  $C_{1-8}$  alkenyl, arylalkyl, substituted arylalkyl, alkylaryl, substituted alkylaryl, aminoarylalkyl or substituted aminoarylalkyl;

$R^7$  is -OH or halogen; and

$R^8$  is hydrogen, halogen or  $C_{1-8}$  alkyl,  
provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen, Z is  
not present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen  
in the manufacture of a medicament for treating a lysosomal storage disorder in a  
patient diagnosed with the same.

2. The use of claim 1, wherein the compound is of Formula II:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen,  $-OH$  or halogen;

$R^3$  is hydrogen,  $-OH$ , halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl,  
wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;

$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a  
cycloalkyl ring, which may be optionally substituted with one or more halogen  
atoms;

$R^6$  is hydrogen, phenylalkyl or substituted phenylalkyl;

Z is optional, when present Z is  $-(CH_2)-$ ,  $-C(=O)-$ ,  $-S(=O)_2NH-$ ,  $-S(=O)_2-$ ,  
 $-S(=O)_2CH_2-$ ,  $C(=O)-NH-$ ,  $-S(=O)_2NR^9-$ ,  $-C(=S)-NH-$  or  $-C(=O)_2CH_2-$ ,

$R^9$  is hydrogen or  $CH_3$ ;

$R^{10}$  is hydrogen or  $CH_3$ ;


$R^5$  is hydrogen or aminophenylalkyl;

$R^7$  is  $-OH$  or halogen; and

$R^8$  is hydrogen, halogen or  $-CH_3$ ,

provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is halogen, Z is not  
present,  $R^7$  is  $-OH$ ,  $R^5$ ,  $R^6$  and  $R^8$  are hydrogen.

3. The use of claim 1, wherein the compound of Formula III:



wherein:

$R^1$  is  $C(R^2)(R^3)(R^4)$ ;

$R^2$  is hydrogen, -OH or halogen;

$R^3$  is hydrogen, -OH, halogen or  $-CH_3$ ;

$R^4$  is halogen,  $-CH_3$ , phenyl, fluorophenyl, methylphenyl, cyclohexylmethyl, wherein when  $R^4$  is a halogen, both  $R^2$  and  $R^3$  cannot be hydrogen;


$R^3$  and  $R^4$  may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;











$R^7$  is -OH or halogen; and












$R^8$  is hydrogen, halogen or  $-CH_3$ ,








provided that  $R^2$  and  $R^3$  cannot both be hydrogen when  $R^4$  is a halogen,  $R^7$  is -OH and  $R^6$  and  $R^8$  are hydrogen.








4. The use of a compound of:




























or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof in the manufacture of a medicament for treating a lysosomal storage disorder in a patient diagnosed with the same.

5. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

6. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

7. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

8. The use of Claim 4, wherein the compound is:



or a pharmaceutically acceptable salt, or solvate thereof.

9. The use of Claim 4, wherein the compound is:




or a pharmaceutically acceptable salt, or solvate thereof.

10. The use of Claim 1, wherein the lysosomal storage disease is Niemann-Pick disease.

11. The use of Claim 1, wherein the lysosomal storage disease is Gaucher's disease.

12. Use of a compound



or a pharmaceutically acceptable salt, or solvate thereof in the manufacture of a medicament for treating Gaucher's disease in a patient diagnosed with the same.